The Effect of CHEP-OB Combination Chemotherapy in Non-Hodgkin's Lymphoma.
- Author:
Won Sik LEE
1
;
Young Don JOO
;
Heung Rae CHO
;
Chan Hwan KIM
;
Chang Hak SOHN
Author Information
1. Department of Internal Medicine, Busan Paik Hospital, Inje University School of Medicine, Busan, Korea. drlee112@hanafos.com
- Publication Type:Original Article
- Keywords:
Non-Hodgkin's lymphoma;
CHEP-OB chemotherapy;
Overall survival
- MeSH:
Bleomycin;
Busan;
Doxorubicin;
Drug Therapy;
Drug Therapy, Combination*;
Etoposide;
Humans;
Lymphoma, Non-Hodgkin*;
Multivariate Analysis;
Prednisolone;
Survival Rate;
Vincristine
- From:Korean Journal of Hematology
2004;39(1):1-9
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: CHOP (cyclophosphamide, adriamycin, prednisolone, vincristine) regimen is still the standard therapy for non-Hodgkin's lymphoma, but its complete response rate & long-term survival rate are 45~55% and 30%, respectively. New chemotherapy regimen will be required for enhancing response rate and duration of survival. We tried to treat non-Hodgkin's lymphoma with newly developing CHEP-OB (cyclophosphamide, adriamycin, etoposide, prednisolone, vincristine, bleomycin) combination chemotherapy which include etoposide, bleomycin in preexisting CHOP regimen. METHODS: 51 patients with non-Hodgkin's lymphoma who admitted to Busan Paik Hospital Inje University between January 1996 and August 2002 were selected. They were treated with CHEP-OB combination chemotherapy given every 3~4 weeks for total 6 cycles. RESULTS: Objective response was achieved in 82.4% of the patients. Complete response (CR) and partial response (PR) rates were 66.7% and 15.7%, respectively. CR rate was significantly lower in patients with T cell immmunophenotype. Five year overall (OS) and failure-free survival (FFS) rate were 61.9%, 54.7%, respectively. Multivariate analysis showed that sex, stage and attainment of CR were factors independently predictive for OS and that stage and attainment of CR were factors independently predictive for FFS. Major side effect was myelotoxicity. CONCLUSION: CHEP-OB combination chemotherapy might be useful as a treatment strategy in non-Hodgkin's lymphoma considering similar response and survival rate, lower toxicity when it is compared with 3rd generation combination chemotherapy. But more effective chemotherapeutic regimen needs to be explored.
